< Back To Leaders

Patrick Vallance

Patrick Vallance, Board of Directors, TransCelerate – Good Clinical Practice

Patrick Vallance

President, Pharmaceuticals R&D, GlaxoSmithKline

Patrick is President, Pharma R&D and a member of the company’s Corporate Executive Team. He is responsible for the pharmaceutical pipeline: leading delivery of current late stage portfolio, and ensuring sustainability of R&D productivity through innovation. 

Patrick joined GSK in May 2006 as Head of Drug Discovery. He transformed GSK’s discovery engine by driving a more entrepreneurial culture. Patrick established the Discovery Investment Board, and by focused small, empowered teams, Discovery Performance Units, on therapy areas with the most promising science. Between June 2010 and December 2011, Patrick integrated discovery and development into Therapy Area Units to sharpen the focus on pipeline delivery and execution.  

Prior to joining GSK, Patrick was a clinical academic and led the Division of Medicine at UCL. He has over 20 years of experience in clinical medicine, general internal medicine, cardiovascular medicine and clinical pharmacology. He was elected to the Academy of Medical Sciences in 1999 and subsequently became its Registrar before leaving to join GSK. 

Translate »

Stay Connected to Transcelerate.